Legal Representation
Attorney
Steven A. Abreu
USPTO Deadlines
Application History
42 events| Date | Code | Type | Description |
|---|---|---|---|
| Nov 6, 2024 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
| Dec 4, 2023 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
| Dec 4, 2023 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED |
| Apr 18, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Apr 17, 2023 | EX5G | S | SOU EXTENSION 5 GRANTED |
| Apr 17, 2023 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Apr 12, 2023 | EXT5 | S | SOU EXTENSION 5 FILED |
| Apr 12, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Oct 7, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Oct 5, 2022 | EX4G | S | SOU EXTENSION 4 GRANTED |
| Oct 5, 2022 | EXT4 | S | SOU EXTENSION 4 FILED |
| Oct 5, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Apr 27, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Apr 25, 2022 | EX3G | S | SOU EXTENSION 3 GRANTED |
| Apr 25, 2022 | EXT3 | S | SOU EXTENSION 3 FILED |
| Apr 25, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Oct 19, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Oct 15, 2021 | EX2G | S | SOU EXTENSION 2 GRANTED |
| Oct 15, 2021 | EXT2 | S | SOU EXTENSION 2 FILED |
| Oct 15, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Apr 24, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Apr 22, 2021 | EX1G | S | SOU EXTENSION 1 GRANTED |
| Apr 22, 2021 | EXT1 | S | SOU EXTENSION 1 FILED |
| Apr 22, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Nov 3, 2020 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Sep 8, 2020 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Sep 8, 2020 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Aug 19, 2020 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Aug 3, 2020 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Aug 1, 2020 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Jul 31, 2020 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Jul 31, 2020 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Apr 1, 2020 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Apr 1, 2020 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Apr 1, 2020 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Feb 20, 2020 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Feb 20, 2020 | GNRT | F | NON-FINAL ACTION E-MAILED |
| Feb 20, 2020 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Feb 19, 2020 | DOCK | D | ASSIGNED TO EXAMINER |
| Feb 10, 2020 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Nov 21, 2019 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Nov 19, 2019 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 001
Biomedical compounds, namely, amino acids; biomedical compounds, namely, peptides, stapled peptides, and synthetic peptides, all comprised of amino acids, for use in scientific and laboratory research; biomedical compounds, namely, miniproteins, and cell-penetrating miniproteins (CPMPs) in raw material form for use in scientific and laboratory research
Class 005
biomedical compounds for medical purposes, namely, amino acids, peptides, stapled peptides, and synthetic peptides, in particular amino acids for the medical treatment of cancer, inflammatory conditions, immunological disorders, cardiovascular conditions, infectious diseases, and neurological conditions; biomedical compounds for medical purposes, namely, miniproteins and cell-penetrating miniproteins (CPMPs) arrays for diagnosing cancer, inflammatory conditions, immunological disorders, cardiovascular conditions, infectious diseases, and neurological conditions
Additional Information
Pseudo Mark
GRIP TIDE
Classification
International Classes
001
005